Industry Snippets: Barron's: Why Big Pharma Is Diving Into Gene Therapy

Barron's published on March 1, 20019 an article about the Big Pharma and the growing interest in Gene Therapy.

“Big drug companies are waking up and saying this is a real technology and that they need to be there,” says Marshall Gordon, senior research analyst at ClearBridge Investments, an active equity manager based in New York.

Gene therapy is growing up as a business, but the science is decades old. So far, the only replacement gene therapy that has been approved by the Food and Drug Administration is Spark’s treatment for a retinal disease that can lead to blindness.

Full article on Barron's website can be found here